Smith & Nephew posts 3% rise in FY sales, sees no Brexit impact

Writer, Stock Market Wire
Thursday, February 7, 2019 - 08:29

British medical equipment manufacturer Smith & Nephew posted a small increase in revenue in its full-year results on Thursday as it said it did not anticipate any significant impact on its business from Brexit.

Full-year revenue rose 3% year on year to $4904m while fourth-quarter revenue was just 1% above prior-year levels at $1294m.

Its trading profit rose to $1123m from $1048m a year earlier while the trading profit margin rose to 22.9% from 22% in 2017.

The company said it did not believe that the UK's decision to leave the EU would have a significant impact on its long-term ability to conduct business into and out of the EU or UK. The UK accounts for approximately 5% of the firm's global revenue and the majority of its manufacturing takes place outside the UK and EU. Nonetheless, the company said it was making good progress with preparations for the various scenarios.

Looking forward, the company said it expected underlying revenue to increase 2.5-3.5% with an expected trading profit margin in the 22.8-23.2% range.

The company would pay a final dividend of $0.22/share, which, together with an interim dividend of $0.14/share, would give a total full-year distribution of $0.36, a year-on-year increase of 3%.

Smith & Nephew also announced five new strategic imperatives, which would form its value-creation plan for the medium term and build on its previously announced new global commercial model.

At 8:29am: (LON:SN.) Smith Nephew PLC share price was +34.75p at 1496.25p


Related content

Smith & Nephew completes acquisition of Osiris for $660m

Smith & Nephew said it had completed its acquisition of regenerative medicine products supplier Osiris for around $660m.

The medical technology group had offered $19.00...

Wed, 17/04/2019 - 14:43


Smith & Nephew to acquire Leaf Healthcare

Smith & Nephew said it had agreed to acquire Leaf Healthcare, a developer of a system for pressure injury prevention and patient mobility monitoring, for...

Mon, 01/04/2019 - 09:46


Smith & Nephew to complete new surgical robots platform by end 2019

Medical technology group Smith & Nephew said its next generation surgical robots platform was planned for completion in late 2019.

A full commercial release was...

Wed, 13/03/2019 - 07:34


Smith & Nephew acquires Osiris Therapeutics for around $660m

Medical technology company Smith & Nephew said it had agreed to acquire regenerative medicine group Osiris Therapeutics for around $660m.

Osiris Therapeutics offered products including...

Tue, 12/03/2019 - 13:07


Broker Forecast - Goldman Sachs issues a broker note on Smith & Nephew PLC

Goldman Sachs today reaffirms its neutral investment rating on Smith & Nephew PLC (LON:SN.) and raised its price target to 1440p (from 1400p).

Broker Forecasts...

Mon, 11/02/2019 - 15:40